Skip to main content

Revvity guidance

  • RVTY · NYSE
  • Instruments
  • Health Care Equipment
  • S&P 500
$149.60+0.50%Close 17 Nov 2026 · Market value $16.67B

In its results release of 3 Nov 2026 (Q3 FY2026), Revvity gave 1 forecast in figures, among them EPS (adjusted) of $5.40 to $5.45 for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 3 Nov 2026

MeasurePeriodGuidanceAs stated
EPS · AdjustedFY2026$5.40 to $5.45For the full year 2026, on a pro forma basis, the Company forecasts total revenue of approximately $2.86 billion, pro forma organic revenue growth of approximately 5%, and pro forma adjusted earnings per share of $5.40-$5.45.

Source: the company's earnings release.

Guidance against results last two years

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
Revenue growthFY2026+4% to +5%Given once—To come
Organic revenue growthFY2026+2% to +3%Given once—To come
EPS · AdjustedFY2026$5.40 to $5.45Raised twice, lowered once—To come
Revenue growthFY2025+3% to +5%Raised once+3.67%Within the range

RVTY in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.